Leerink analyst Daina Graybosch downgraded Lava Therapeutics (LVTX) to Market Perform from Outperform with a price target of $2, down from $11, following the company’s discontinuation of LAVA-1207, which was in Phase 1 development for metastatic castration-resistant prostate cancer. The firm acknowledges several valid prostate cancer-related challenges that may not necessarily read through to other targets and indications. That said, Leerink finds it difficult to give its platform the benefit of the doubt.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX: